Saturday, August 18, 2018
 
 
Company News: Page (1) of 1 - 07/30/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Embolization Particle Market to Grow With Steadily Numbers by 2023 Registering a CAGR over 9.64% with Boston Scientific Corporation, Guerbet, BTG International, etc. by 2023 - Asserts MRFR

(July 30, 2018)


"Embolization Particle Market"
Market Research Future published a cooked research report on “Global Embolization Particle Market Research Report - By Major Industry Trends, Business Analysis, Major Segments and Sub segments. Rising Prevalence of Cancer & Demand for New Diagnostic Techniques Accelerate the Growth of the Market. By 2023

Embolization Particle is a minimally invasive therapy used in many procedures as a part of interventional radiology. Embolization is used to stop bleeding as well as to treat tumors that cannot be removed by surgery by stopping its blood supply. The invention of Embolization Particle in therapeutics has offered some exciting possibilities. While Embolization can also be used with ablation, it may not be a good option for some patients whose liver has been damaged by diseases such as cirrhosis or hepatitis.

The use of Embolization in the field of medicine as a whole has revolutionized the way of diagnosis, treatment, and prevention. Hence, the market for Embolization Particle is blooming currently, with the growing prevalence of cases of tumors. The augmenting demand for noninvasive therapies predominantly drives the market growth.

Get Premium Sample copy @ https://www.marketresearchfuture.com/sample_request/4815

Acknowledging the galvanization the market perceives, demonstrating the growth prospects; Market Research Future (MRFR), in its recently published market forecast asserts that the global Embolization Particle market will register a striking CAGR of 9.64 % throughout the forecast period (2017 – 2023) garnering accruals of USD 1,909.76 Mn. by 2023.

Also, growing incidence of cancer and other metabolic diseases have fueled the growth of Embolization Particle market. Additional factors contributing to the market growth include the growing population, urbanization and improving economic conditions that are increasing access to the quality healthcare and quality of life of people.

On the other hand, unavailability of interventional neuroradiologists and interventional neuroradiology (INR) labs along with the lack of regulatory standards in the examination of Embolization Particle and higher cost of the treatment are some of the key factors impeding the market growth.

Global Embolization Particle Market Competitive Analysis

Key Players are actuated to bring innovations in the therapy with minimum adverse effects, as well as to target emerging applications to leverage growth opportunities. They are focusing on R&D in order to develop the therapy further.

Key Players:

Market players driving the global embolization particle market include Guerbet, Boston Scientific Corporation, BTG International Ltd, Sirtex, Medtronic, Merit Medical, and Terumo. Profiling them in its analysis MRFR finds the strategies helping them to stay at the forefront of competition.

Get Stunning Discount @ https://www.marketresearchfuture.com/check-discount/4815

Global Embolization Particle Market Segmentation

Global Embolization Particle Market is segmented into five key dynamics for the convenience of understanding;

By Product Types: Radioembolization and Drug Eluting Beads among others.

By Applications: Oncology, Peripheral Vascular Disease, and Neurology among others.

By Levels of Occlusion: Proximal and Distal among others. 

By End-Users: Hospitals, Clinics and ambulatory services among others.

The Radioembolization segment accounted for the largest market share in 2016 and is estimated to grow at 10.01% CAGR approx. during the forecast period from 2017-2023.

Global Embolization Particle Market Regional Analysis

Globally North America leads the Embolization Particle market with the significant market share. The Market is expected to grow phenomenally from 2017 to 2023. Factors substantiating the market growth include the growing number of patients suffering from tumors coupled with the high healthcare expenditures, significant developments in the healthcare domain, and focus of research institutions on advent technologies for new and advanced diagnosis and treatment methods. Well-defined per capita healthcare expenditure is undoubtedly a key driving force behind the market growth in the region.

Moreover, the growing number of centers offering embolization particle therapy coupled with the availability of advanced infrastructures & devices, and availability of skilled healthcare professional contributions to the market growth in the region. The region is expected to reach the valuation of USD 703.13 Mn. by 2023.

The US, backed by the technological advances and availability of funding for the development of new therapeutics and treatment accounts for the major contributor to the market growth. Moreover, the presence of the well-established players also drives the market for Embolization Particle in this region.

Europe emerging as a lucrative market for Embolization Particle will expand with a phenomenal CAGR.  The resurging economy in the region is expected to foster the regional market growth.  Besides, availability of technologically advanced devices and the proliferation of quality healthcare along with the increasing healthcare cost mushrooms the growth of the market in the region.

Asia Pacific market for the Embolization Particle is expected to perceive the fastest growth by 2023 registering a CAGR of 10.11% from 2017 to 2023. India and China backed by the huge population, and the availability of low-cost therapies will lead the regional market. Moreover, the fastest growing healthcare sector coupled with the large unmet needs over the forecast period will provide impetus to the market growth.

Industry/Innovation/Related News:

March 21, 2018 – Fluidx Medical Technology (US), a new proprietary in situ setting embolic presented its new vascular embolic device - GPX at the 2018 Society of Interventional Radiology conference held at Los Angeles, USA. GPX is a biocompatible particle embolic loaded in a pre-packaged syringe in a low-viscosity state. The device is still under development and not FDA cleared yet.  After injecting into a blood vessel through a standard catheter, GPX can fill the targeted vessel and therapeutically slow or stop blood flow.

Have Any Query, Ask to Expert @ https://www.marketresearchfuture.com/enquiry/4815

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact

Company Name: Market Research FutureContact Person: Abhishek Sawant


Email: [email protected]
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/embolization-particle-market-4815



Source: www.abnewswire.com


Page: 1


Related Keywords:Business,Health & Medicine,Pharmaceuticals & Biotech,U.S,World,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
  • Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

    Cancer
  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck
  • Colorado Pain Care Broadens Practice to Include Cancer Patient Treatment in Denver, CO and Surrounding Area
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines